VBI Vaccines Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffery R. Baxter FCMA
- Full Time Employees
- 131
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 160 Second Street Cambridge MA United States of America 02142
- IPO Date
- Apr 26, 2010
- CIK
- 0000764195
- Website
- vbivaccines.com
- Similar Companies
- Business
- VBI Vaccines Inc. (Nasdaq: VBIV) is a biopharmaceutical company that develops and commercializes vaccines and immunotherapeutics targeting infectious diseases and immuno-oncology using proprietary enveloped virus-like particle (eVLP) platform technology and mRNA-launched eVLP (MLE) platform technology. The company offers PreHevbrio, a three-antigen recombinant hepatitis B vaccine approved for prevention of infection in adults 18 years and older; Sci-B-Vac, a third-generation single-antigen hepatitis B vaccine; and investigational candidates including VBI-1901, an immunotherapy for recurrent glioblastoma; VBI-2601, a hepatitis B immunotherapeutic; cytomegalovirus (CMV) vaccine candidates; and pan-coronavirus vaccines such as VBI-2901, VBI-2902, and VBI-2905. These products and programs leverage virus-like particles that mimic natural viral structures to elicit potent immune responses for prevention and treatment across adult, pediatric, and newborn populations. Founded in 2001 (formerly known as SciVac Therapeutics Inc., renamed in May 2016) and headquartered in Cambridge, Massachusetts, VBI Vaccines maintains research and development facilities in Ottawa, Ontario, Canada, and formerly operated a research and manufacturing site in Rehovot, Israel. The company serves global markets with a focus on unmet needs in hepatitis B, cytomegalovirus, coronaviruses, and aggressive cancers like glioblastoma, through collaborations including those with Brii Biosciences Limited, the National Research Council of Canada, and the Coalition for Epidemic Preparedness Innovations. In April 2024, VBI Vaccines announced an agreement with Brii Biosciences to sell its Rehovot manufacturing capabilities and related assets, intellectual property for VBI-2601, and grant an exclusive Asia Pacific (excluding Japan) license for VBI-1901, potentially yielding up to $33 million in consideration and reducing debt by approximately 70% to $17 million upon completion targeted for June 2024. Later in 2024, the company initiated restructuring proceedings under the Canadian Companies' Creditors Arrangement Act (CCAA) to review strategic alternatives, issued a voluntary nationwide recall of all PreHevbrio vaccine within expiry due to discontinuation of operations, permanently ceased U.S. distribution of PreHevbrio, and began rapidly winding down U.S. operations. Additional recent developments include expanded strategic partnerships with the Canadian government for the MLE platform, positive interim Phase 2b data for VBI-1901 in recurrent glioblastoma presented at the 2024 ASCO Annual Meeting, and a $2 million registered direct offering in 2024. As of early 2025, VBI Vaccines plans an office move impacting its Cambridge location.
VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
VBI Vaccines Announces Results of Annual General Meeting
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Reports First Quarter 2024 Financial Results
VBI Vaccines Reports Full Year 2023 Financial Results
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
VBI Vaccines Reports Third Quarter 2023 Financial Results
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
VBI Vaccines' pan-coronavirus vaccine candidate produced broad protection against variants of concern
VBI Vaccines' Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results